Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$955,458Cash on Hand
0.9mo Cash Runway
Follow HCWB by emailGet an email when HCWB reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about HCWB, unsubscribe in one click. Privacy
📣 What HCWB Says Is Next
first half of 2027 · “As a result of discussions at a recent Type B meeting with the U.S. Food and Drug Administration (“FDA”), the FDA provided the Company with clear guidance for the next steps to prepare its IND application to support a first-in-human clinical study to evaluate HCW11-018b in solid tumors, which the Company intends to file in the first half of 2027.”
Company press release, Nov 16, 2026 · SEC filing
first quarter of 2027 · “With this financing, the Company believes it has funding in place to reach the milestone of completion of the Phase 1 clinical trial for HCW9302 and determining the Recommended Phase 2 Dose level, which are expected in the first quarter of 2027.”
Company press release, Nov 16, 2026 · SEC filing
in March 2027 · “The Company intends to present the full results of the Phase 1 clinical trial in an invited oral presentation at the 9 th Treg-Directed Therapies Summit in March 2027 in Boston, Massachusetts.”
Company press release, Nov 16, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 16, 2026 ·
Earnings Reported Q3 2026 results: revenue of $55,463 for the quarter and $6.7 million for nine months, after terminating the AlloTera license and completing the Trimmune license. Q3 R&D fell to $1.2 million and G&A to $1.4 million. Form 8-K · SEC filing · Press release
Nov 16, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Financing HCW Biologics closed a Streeterville Capital debt financing on Nov 4, 2026, receiving $3.0 million upon closing plus $7.0 million more held in a controlled account, subject to conditions. Proceeds will support the HCW9302 Phase 1 alopecia areata study. Form 8-K · SEC filing · Press release
Oct 2, 2026 ·
Financing Registers resale of up to 1,807,228 shares for an existing institutional investor, tied to a September 2026 private placement of 903,614 units at $1.6599 per unit. The units include pre-funded warrants and common warrants exercisable at $1.66 after stockholder approval, for about $1.5 million in gross proceeds. Form S-1 · SEC filing
Oct 1, 2026 ·
Shareholder vote HCW Biologics seeks stockholder approval, for Nasdaq Rule 5635(d), to issue Common Warrants exercisable for up to 618,682 shares at $2.585 per share tied to a $1.6 million private placement completed July 29, 2026. The special meeting is set for November 17, 2026, with a record date of September 21, 2026. Form DEF 14A · SEC filing
Sep 24, 2026 ·
Financing Entered a $1.5 million private placement with an existing institutional investor, selling 903,614 units at $1.6599 per unit through Maxim Group LLC. Each unit includes a pre-funded warrant at $0.0001 and a common warrant at $1.66, issuable only after stockholder approval. Form 8-K · SEC filing · Press release
Sep 10, 2026 ·
Shareholder vote HCW Biologics amended its preliminary proxy statement. The board dropped Proposal No. 2, a proposed amended performance-based equity plan, after stockholder feedback. The Special Meeting date, record date and certain other dates were also changed. Form 8-K · SEC filing
Sep 8, 2026 ·
Deal Entered an exclusive worldwide distribution agreement, excluding China, with Akron Biotech for HCW11-006 as a non-injectable cell therapy manufacturing reagent, for a five-year term. Form 8-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jul 2027 · Phase 1 · Recruiting · HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not HCWB's own candidates): Paclitaxel, HCW9302, an IL-2 fusion protein.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
HCWB holds $955,458 in cash and short-term investments (as of Sep 30, 2026) and burns about $3.3M/quarter from operations,
an estimated runway of 0.9 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:62 · High
Cash runway 1 months +40
Going-concern doubt in the latest 10-Q +15The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the condensed financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant…10-Q, Nov 2026
Share count 3,139,938 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full HCWB picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HCWB and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.